Navigation Links
InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Date:9/2/2008

- $15 million development milestone payment to InterMune -

- Roche to lead ITMN-191 program in Phase 2 -

BRISBANE, Calif., Sept. 2 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that InterMune has earned a $15 million development milestone under its development collaboration with Roche for the hepatitis C virus (HCV) NS3 protease inhibitor compound ITMN-191 (referred to as R7227 at Roche), currently in a Phase 1b clinical trial in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin).

Under the terms of their 2006 collaboration agreement, the clinical program for ITMN-191 is now being transitioned to Roche which, starting in Phase 2, will have primary responsibility for completing the global development and registration program.

Nick Cammack, Ph.D., Global Head of the Virology Disease Biology Area, Roche, said, "Protease inhibition is a crucial aspect of our HCV strategy, which is focused on developing clinically differentiated medicines for patients. Our continued enthusiasm for ITMN-191/R7227 underscores our confidence in InterMune and we now plan to rapidly move the program into Phase 2 development."

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "We are very pleased to have led the preclinical development, conducted three Phase 1 clinical trials and with Roche, optimized the manufacturing of ITMN-191 active pharmaceutical ingredient (API) since the collaboration was announced less than two years ago. We look forward to the continued strong relationship with Roche as we together develop protease inhibitor therapies in combination with current standard of care and with other direct antiviral agents."

<
'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Eckert & Ziegler ... Spectrometry (AMS) services to the pharmaceutical and biotech industry, ... the company in the position of Director of Science ... broad and valuable experience in drug metabolism and bioanalysis ...
(Date:1/22/2015)... 2015  Transwestern | RBJ today announces the firm brokered a ... Shire a leading biopharmaceutical company, at Two Ledgemont Center in ... Robert Richards , president, and Brian Cohen , senior ... five-floor building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... CO / Rootstown, OH (PRWEB) January 22, 2015 ... detection platform, announced today that it has received AOAC-PTM Certifications ... O45, O1O3, O111, O121, and O145; collectively referred to as ... coli) O157, at 1 colony forming unit (cfu) per 325 ...
(Date:1/22/2015)... 2015 Controlled Substance Compliance Services (CSCS), ... companies check the legal requirements around using controlled substances ... , As their international operations expand and become ... solutions built as a result of the first phase ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Global Compliance Service for Controlled Substances to Expand to China 2
... a developer of follow-on biologics and biopharmaceuticals, announced,today that ... Stewart Fourth Annual Growth Conference on Thursday, July 10, ... conference will take place at the Mandarin Oriental Hotel ... July 10. Insmed,s,presentation will be webcast live over the ...
... Inc.,(Nasdaq: ATSI ), manufacturer and marketer of ... has obtained new in vivo,data to support the ... Heart Valve., (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ), ... in Lausanne, Switzerland,on May 4, 1992 by Professor ...
... July 8, 2008Biotech and pharmaceutical firms are developing ... the complicated drug discovery process, reports Genetic ... Most successful approaches rely on a combination of ... tools, according to an article in the July ...
Cached Biology Technology:Insmed to Present at Collins Stewart Fourth Annual Growth Conference 2ATS Medical Confirms Excellent Durability of the ATS Open Pivot Mechanical Heart Valve 2
(Date:12/11/2014)... 2014 Research and Markets , ... has announced the addition of the "Biometrics Market ... One major trend emerging in this ... technology, it is important to upgrade biometric solutions to ...
(Date:12/11/2014)... 10, 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately need to ... site key or the answer to your secret question. What,s your ... Today, Hoyos Labs , a digital infrastructure security company, launches ... the frustration that comes with usernames, passwords and PINs – ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... nanoparticles, tiny pieces of gold so small that they ... in electronics, healthcare products and as pharmaceuticals to fight ... the nanoparticles requires dangerous and extremely toxic chemicals. While ... of nanoparticles in the near future, researchers have been ...
... Can a road-trip across eastern North America, ancient ice sheets, ... trees? Julie Godbout and colleagues from the Universit Laval, ... Canada to collect samples from jack pine trees would shed ... genetics. About 20,000 years ago, ice sheets covered ...
... genetic material. Endogenous retroviruses (ERV) are those sequences derived ... that, being incorporated in the genome, are transmitted from ... the expression of ERV can benefit the host if ... the protection of the embryo. However, given its pathogenic ...
Cached Biology News:Cinnamon can replace harmful chemicals used to create nanoparticles 2Blast from the past: Jack pine genetics support a coastal glacial refugium 2Blast from the past: Jack pine genetics support a coastal glacial refugium 3Ph.D. thesis describes 35 hitherto unknown families of endogenous retroviruses 2
Component in MasterPure™ Purification Kits...
Mouse monoclonal [TU-20] to beta III Tubulin (FITC) ( Abpromise for all tested applications). entrezGeneID: 10381 SwissProtID: Q13509...
Phospho-FKHR (Thr24)/FKHRL1 (Thr32) Antibody...
Mouse anti-Insulin-Like-3 Class: Antibody Product Group: Adipokine and Obesity related...
Biology Products: